An acneiform eruption due to erlotinib: Prognostic implications and management

被引:16
作者
Journagan, S [1 ]
Obadiah, J [1 ]
机构
[1] St Louis Univ, Dept Dermatol, St Louis, MO 63103 USA
关键词
D O I
10.1016/j.jaad.2005.08.033
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
[No abstract available]
引用
收藏
页码:358 / 360
页数:3
相关论文
共 5 条
[1]
Herbst Roy S, 2004, Clin Lung Cancer, V6 Suppl 1, pS7, DOI 10.3816/CLC.2004.s.009
[2]
Herbst Roy S, 2003, Clin Lung Cancer, V4, P366, DOI 10.3816/CLC.2003.n.016
[3]
Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor [J].
Lee, MW ;
Seo, CW ;
Kim, SW ;
Yang, HJ ;
Lee, HW ;
Choi, JH ;
Moon, KC ;
Koh, JK .
ACTA DERMATO-VENEREOLOGICA, 2004, 84 (01) :23-26
[4]
Perez-Soler Roman, 2003, Oncology (Williston Park), V17, P23
[5]
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy [J].
Raymond, E ;
Faivre, S ;
Armand, JP .
DRUGS, 2000, 60 (Suppl 1) :15-23